Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL18261961 | 0.92 | ALDH1A1 (0.36) | DGAT1TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL2204111 | 0.87 | CYP4F2 (0.39) | DGAT1TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL5000217 | 0.87 | CYP4F2 (0.39) | DGAT1TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL21033777 | 0.86 | KDM4E (0.33) | DGAT1KDM4EPKMALDH1A1CYP4F2 | |
| SCHEMBL16453917 | 0.83 | KDM4E (0.34) | DGAT1KDM4EPKMALDH1A1HSD17B10 | |
| SCHEMBL354285 | 0.81 | CYP2C19 (0.37) | DGAT1ALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL28860642 | 0.79 | EPHX1 (0.39) | KDM4EPKMCYP4F2CYP4A11 | |
| SCHEMBL18597562 | 0.79 | CYP4F2 (0.39) | DGAT1KDM4EPKMALDH1A1HSD17B10 | |
| SCHEMBL15367676 | 0.78 | FDPS (0.33) | KDM4EPKMHSD17B10CYP4F2CYP4A11 | |
| SCHEMBL2477744 | 0.77 | CYP4F2 (0.39) | DGAT1TSHRHCAR2KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787413-B2 | Derivatives of curcuminoids and use thereof as an anticancer agent | CHINA MEDICAL UNIVERSITY (TW) | 2020-09-29 | — | — | US | disclosed |
| US-20190161430-A1 | NOVEL DERIVATIVES OF CURCUMINOIDS AND USE THEREOF AS AN ANTICANCER AGENT | CHINA MEDICAL UNIVERSITY (TW) | 2019-05-30 | — | — | US | disclosed |
| US-8551963-B2 | Imidazolothiazole compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551963-B2 | Imidazolothiazole compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551963-B2 | Imidazolothiazole compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-22 | — | — | US | disclosed |
| EP-2358725-A1 | Imidazolothiazole compounds as modulators of protein kinase | Ambit Biosciences Corporation (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010054058-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE | AMBIT BIOSCIENCE CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054058-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE | AMBIT BIOSCIENCE CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161430-A1 | NOVEL DERIVATIVES OF CURCUMINOIDS AND USE THEREOF AS AN ANTICANCER AGENT | HPGDS, MYC, HCCS | DGAT1 2390/4885TSHR 4822/4885HCAR2 259/4885 |
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GRK2, GRK3, GRK4 | DGAT1 2600/4885TSHR 620/4885HCAR2 482/4885 |
| US-10787413-B2 | Derivatives of curcuminoids and use thereof as an anticancer agent | HPGDS, DHFR, MYC | DGAT1 2339/4885TSHR 4815/4885HCAR2 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.